Parosmia was associated with significantly better quantitative olfactory scores but worse quality-of-life scores.
Literature Reviews » COVID19
Clinical suspicion of acute invasive fungal rhinosinusitis (AIFR) among COVID-19 patients and early management with antifungal therapy and surgical debridement is essential for better outcomes and higher survival.
Due to the high prevalence of taste disorders as an early clinical symptom in patients with COVID-19, proper screening and evaluation should be performed.
Olfactory dysfunction (OD) presence does not seem to be useful in identifying subjects at risk for being COVID-19 super spreaders.
Nasal and nasopharyngeal lavages appear to be well tolerated and highly reliable in detecting SARS-CoV-2.
This analysis highlights the need for close monitoring of patients with sleep apnea who become infected with COVID-19.
Early tracheotomy is related to reduced need for mechanical ventilation and shorter ICU stay in severe COVID-19 cases.
Chemosensory dysfunction is very common in COVID-19 and, although most people regain function within the first 28 days.
Evidence indicates that the prevalence of olfactory dysfunction in COVID-19 patients is 48.85%.
Significant aerosol levels were generated during cadaveric simulation of mastoidectomy, and aerosol spikes were appreciated during cochlear implantation in live patients.